Nicholas J. Vogelzang, MD
Ten years ago, Nicholas J. Vogelzang, MD, helped design a study of docetaxel added to first-line androgen deprivation therapy (ADT) in men with newly diagnosed metastatic, hormone-sensitive prostate cancer.
Making the regimen even more accessible is the fact that its cost is expected to be relatively low, since both agents are available in generic form, Vogelzang said. “The biggest cost is probably the anti-nausea drugs, and this is not a particularly nausea-inducing regimen, so the cost is pretty modest,” he said.
Key Findings Released at ASCO
In the 8-year, National Cancer Institute (NCI)-led study, 790 men with newly diagnosed metastatic prostate cancer—two-thirds of them with high-extent disease—were randomly assigned 1:1 to receive either ADT alone or ADT with docetaxel, which was dosed at 75 mg/m2
every 3 weeks for 6 cycles within 4 months of starting ADT. After the combination cohort completed 6 courses of docetaxel, all patients continued on ADT alone. The patients were stratified so that the study arms would be balanced, said Christopher Sweeney, MBBS, a medical oncologist at the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston who presented the study’s findings at a June 1 press briefing during the ASCO meeting.
... to read the full story